Site Map | Contact Us		Celgene Global------------AustraliaBeLuxCanadaCelgene EUChinaDenmarkFinlandFranceGermanyHong KongIrelandItalyJapanMalaysiaNorwayPhilippinesRussiaSingaporeSouth KoreaSpainSwedenTaiwanThailandThe NetherlandsTurkeyUnited Kingdom------------World Map		Font Size				Print Page

Bruton's Trosine Kinase Inhibitor

E. Evans, et al. Clinical Development of AVL-292: A Potent, Selective Covalent Btk Inhibitor for the treatment of B Cell Malignancies, ASH Annual Meeting, Dec 10-13, San Diego, California.

H. Eda, et al. Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma, ASH Annual Meeting, Dec 10-13, San Diego, California.

E. Evans, et al. Translation Medicine of a Selective Inhibitor of Btk in Rheumatic Diseases: Pharmacology and Early Clinical Development. American College of Rheumatology, November 5-9, Chicago, Illinois.

M. Labenski, et al. InVitro Reactivity Assessment of Covalent Drugs Targeting Bruton's Tyrosine Kinase. 17th North America Regional Meeting of International Society for the Study of Xenobiotics, October 16-20, Atlanta, Georgia.

E. Evans, et al. AVL-292: A Targeted Therapy For Bruton's Tyrosine Kinase in B Cell Malignancies. 16th Congress of the European Hematology Association, London UK.

E. Evans, et al. Bruton's Tyrosine Kinase from Bench to Bedside: Covalently Silencing B Cells with AVL-292. Keystone Symposium: B Cells: New Insights into Normal vs. Dysregulated Function, April 12-17th, Whistler, BC.

Bruton's Trosine Kinase Inhibitor

R. Karp, et al. Inhibition of Btk with AVL-292 Translates to Protective Activity in Animal Model of Rheumatoid Arthritis. 16th International Inflammation Research Association Conference, Chantilly, VA.

Bruton's Trosine Kinase Inhibitor

E. Evans, et al. A novel platform-based approach to silence oncoproteins using small molecule therapeutics - application to Bruton's yyrosine kinase. American Association for Cancer Research (AACR) 100th Annual Meeting, Denver, Colorado.